Spark Therapeutics Inc. (ONCE)

108.06
0.99 0.91
NASDAQ : Health Technology
Prev Close 109.05
Open 108.72
Day Low/High 107.85 / 109.10
52 Wk Low/High 34.53 / 114.20
Volume 300.04K
Avg Volume 1.97M
Exchange NASDAQ
Shares Outstanding 37.75M
Market Cap 4.06B
EPS -2.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Trading Roku Stock as Downgrades Sap Its Run to New Highs

Trading Roku Stock as Downgrades Sap Its Run to New Highs

Roku was hit with a pair of downgrades on Wednesday

SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Spark Therapeutics, Inc. - ONCE

SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Spark Therapeutics, Inc. - ONCE

NEW YORK, March 11, 2019 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating Spark Therapeutics, Inc.

Win, With or Without China: Cramer's 'Mad Money' Recap (Monday 2/25/19)

Win, With or Without China: Cramer's 'Mad Money' Recap (Monday 2/25/19)

Jim Cramer asks whether there aren't enough good things happening that we can sustain an advance without a China deal.

3 Things to Know at Market Close: ETF Inflows, Spark Therapeutics, Palo Alto

3 Things to Know at Market Close: ETF Inflows, Spark Therapeutics, Palo Alto

ETFs could see big inflows again and Sparks stock soars; these are among the important market items today.

Dow Closes Modestly Higher After Trump Extends China Tariff Deadline

Dow Closes Modestly Higher After Trump Extends China Tariff Deadline

The Dow Jones Industrial Average rose modestly Monday after Donald Trump said he will delay increasing tariffs on China-made goods.

Jim Cramer: How to Win Now, With or Without China

Jim Cramer: How to Win Now, With or Without China

If we can advance without China then who the heck knows where we can go with it.

Spark Therapeutics Rockets as Roche Pays $4.3 Billion for Gene Therapy Experts

Spark Therapeutics Rockets as Roche Pays $4.3 Billion for Gene Therapy Experts

Spark Therapeutics shares more than double Monday after the gene therapy specialist agreed to a $4.3 billion takeover by Switzerland-based Roche Holding, the world's biggest maker of cancer treatments.

Roche Deal for Spark Therapeutics Shows Biotech M&A Spark Hasn't Died

Roche Deal for Spark Therapeutics Shows Biotech M&A Spark Hasn't Died

Acquisition deals for biotech companies at the start of 2019 are giving the sector a nice boost; here are other names that could be merger candidates.

Trade Talks, Spark, Buffett, Kraft Heinz, 'Green Book' - 5 Things You Must Know

Trade Talks, Spark, Buffett, Kraft Heinz, 'Green Book' - 5 Things You Must Know

U.S. stock futures rise after Donald Trump says he will delay increasing tariffs on China-made goods; Swiss drug giant Roche to buy Spark Therapeutics for about $4.8 billion; Warren Buffett wants to make an 'elephant-sized acquisition'; Kraft Heinz reportedly reviewing options for Maxwell House.

Stocks Gain, China Surges, as Trump Delays Tariffs Amid Trade Talk Progress

Stocks Gain, China Surges, as Trump Delays Tariffs Amid Trade Talk Progress

StocksGlobal stocks traded higher Monday after President Donald Trump said he would delay the increase of tariffs on China-made goods, set to kick-in on March 1, following "substantial progress" over two weeks of trade talks between Washington and Beijing.

Roche to Buy Spark for $4.8 Billion

Roche to Buy Spark for $4.8 Billion

The price is nearly $3 billion over Spark's market cap of $1.95 billion as of Friday's close. Deal is slated to close in the second quarter of 2019.

Roche Aims to Buy Spark for $5 Billion: Wall Street Journal

Roche Aims to Buy Spark for $5 Billion: Wall Street Journal

Predicted price would be nearly $3 billion over Spark's market cap as of Friday's close, but Roche spokesman claims report is 'market rumor.'

First Week Of February 15th Options Trading For Spark Therapeutics (ONCE)

First Week Of February 15th Options Trading For Spark Therapeutics (ONCE)

Investors in Spark Therapeutics Inc saw new options become available this week, for the February 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ONCE options chain for the new February 15th contracts and identified one put and one call contract of particular interest.

Interesting ONCE Put And Call Options For November 16th

Interesting ONCE Put And Call Options For November 16th

Investors in Spark Therapeutics Inc saw new options become available this week, for the November 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ONCE options chain for the new November 16th contracts and identified one put and one call contract of particular interest.

3 Biotech Stock Favorites to Bet on Today: Top Analysts

3 Biotech Stock Favorites to Bet on Today: Top Analysts

Follow the experts. These biotech stocks have Wall Street's best analysts getting bullish.

Pfizer Initiates Pivotal Phase 3 Program For Investigational Hemophilia B Gene Therapy

Pfizer Initiates Pivotal Phase 3 Program For Investigational Hemophilia B Gene Therapy

Pfizer Inc. (NYSE:PFE) and Spark Therapeutics (NASDAQ:ONCE) announced today that Pfizer initiated a Phase 3 open-label, multi-center, lead-in study ( NCT03587116) to evaluate the efficacy and safety of current factor IX prophylaxis replacement therapy in...

First Week Of ONCE August 17th Options Trading

First Week Of ONCE August 17th Options Trading

Investors in Spark Therapeutics Inc saw new options begin trading this week, for the August 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ONCE options chain for the new August 17th contracts and identified one put and one call contract of particular interest.

Spark Therapeutics Reaches Analyst Target Price

In recent trading, shares of Spark Therapeutics Inc have crossed above the average analyst 12-month target price of $78.22, changing hands for $78.53/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Spark Therapeutics Reports 2017 Financial Results And Recent Business Progress

Spark Therapeutics Reports 2017 Financial Results And Recent Business Progress

U.S. Food and Drug Administration (FDA) grants breakthrough therapy designation to SPK-8011 for hemophilia A

Short Interest Increases 30% For ONCE

Short Interest Increases 30% For ONCE

The most recent short interest data has been released for the 12/29/2017 settlement date, which shows a 1,115,785 share increase in total short interest for Spark Therapeutics Inc , to 4,833,489, an increase of 30.01% since 12/15/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

TheStreet Quant Rating: D+ (Sell)